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Background  and aim: This study  was performed to
assess  the  effects  of  an  exposure  to  a  pure
(1® 3)-b -D-glucan,  a  cell  wall  component  of  fungi,
plants and certain bacteria.
Methods: Twenty-one healthy subjects inhaled saline
or (1® 3)-b -D-glucan suspended in saline in a random,
double-blind, cross-over design. They were examined
before  exposure  and  24  and  72h  afterwards  with
spirometry, blood sampling and collection of induced
sputum.  Differential  cell  counts  and  eosinophilic
cationic protein (ECP) were determined in blood and
sputum, and myeloperoxidase (MPO), tumour necro-
sis factor-a (TNF-a ), and interleukin (IL)-8 and IL-10
were determined in sputum supernatants. TNF-a was
determined  after  cultivation  of  blood  mononuclear
cells.
Results: In sputum, inhalation of saline caused a sig-
nificant increase in ECP and TNF-a . (1® 3)-b -D-Glucan
inhalation  caused  a  further  increase  in  these  cyto-
kines, although not statistically significantly different
from  the  increase  induced  by  inhalation  of  saline
alone.  In  blood,  the  number  of  eosinophils  was
significantly decreased 72h after the challenge with
(1® 3)-b -D-glucan. This effect was not found after the
inhalation  of  saline  alone.  TNF-a production  from
stimulated blood mononuclear cells was significantly
decreased 72h after the (1® 3)-b -D-glucan inhalation
as  compared  with  the  increase  induced  by  saline
inhalation.
Conclusions: The results suggest that (1® 3)-b -D-glucan
causes a different type of response as compared with
inflammatory  agents  such  as  bacterial  endotoxin
that  cause  a  neutrophil-dominated  inflammatory
response.
Key  words:  (1® 3)-b -D-Glucan,  Inflammatory  markers,
Cytokines, Induced sputum
Introduction
Microbial cell  wall  components are  important  con-
stituents  in  organic  dusts.1 Among  the  most  well
known of these are bacterial endotoxins. Endotoxin
has  been  related to  several  effects  in  a  number  of
experimental  and  epidemiological  studies.2–5 A
review of the different  effects and a suggestion  for
guidelines has previously been presented.3
Glucan, a cell-wall component of fungi, plants and
certain bacteria, may also be present in organic dusts.
Glucans  are  composed  of  glucopyranosyl  subunits
that  are  connected  by  a or  b interchain  linkages
consisting of 1® 3, 1® 4, or 1® 6 bonds.6–8 Glucans
in  which  subunits  are  connected  by  (1® 3)-b -D
interchain  linkages  have  potent  immunobiological
effects.9–10 Results from in vitro and in vivo experi-
ments  suggest  that  glucans  can  bind  to  cells  by
receptors,  stimulate  bone  marrow,  activate  macro-
phages and induce production of cytokines such as
interleukin (IL)-1 and IL-2.9,11–14 In vitro studies show
that grifolan, a glucan isolated from Grifola frondosa,
stimulates  the  secretion  of  inflammatory  cytokines
such  as  tumour  necrosis  factor-a (TNF-a )  and  IL-6
from cultured macrophages.14The effects after inhala-
tion are less well known.
In an animal model in which inflammation in the
airways  was  induced  by  exposure  to  endotoxin
(lipopolysaccharide  (LPS)),  inhalation  of
(1® 3)-b -D-glucan did not cause an increase in  neu-
trophil  numbers,  which  is  the  hallmark  of  LPS
exposure. However, a single exposure to aerosolised
(1® 3)-b -D-glucan reduced the invasion of neutrophils
caused by exposure to LPS.15 A sub-chronic exposure
to glucan induced an increased number of eosinophils
in  the  trachea.16 Repeated  exposures  have  also
suggested  that (1® 3)-b -D-glucan  can potentiate the
inflammatory effect of LPS and cigarette smoke.16–18
Airborne (1® 3)-b -D-glucan  has been measured in
occupational  and  general  environments with  levels
ranging up to 370ng/m3. As effects have been found
in  animal  inhalation  studies  at  considerably  lower
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(1® 3)-b -D-glucan  in  humans.  In  previous  investiga-
tions  in  which  human  subjects  inhaled  pure
(1® 3)-b -D-glucan (Curdlan), a slight  increase in the
intensity of throat irritation and skin symptoms was
observed.19,20
The purpose of this study was to further assess the
effects of an acute exposure to pure (1® 3)-b -D-glucan
in  healthy  human  subjects  and  to  compare  two




The study group comprised twenty-one healthy sub-
jects (eight males and 13 females) recruited among
students at the local university. The mean age was 23
years, with a range of 20–31 years. Potential subjects
were interviewed using a questionnaire, and inclusion
criteria were never smokers, no current colds, no self-
reported allergy, no chronic bronchitis and no physi-
cian-diagnosed  asthma.21 Questions  were  posed
about  the  odour  of  moulds,  visible  mould  growth,
dampness and water damage in the subjects homes.
None  of  the  subjects  reported  signs  of  mould
contamination in their homes. They were also non-
atopic  as  defined  by  a  negative  reaction  in  the
Phadiatop test.22
Study design
In  a  random,  double-blind  fashion,  the  subjects
inhaled  saline  or  grifolan,  a  pure  (1® 3)-b -D-glucan
suspended in saline using a cross-over design. They
were examined before the exposures and 24 and 72h
after. Examinations consisted of spirometry measure-
ments and collection of blood and induced sputum
samples.  Differential  cell  counts  and  eosinophilic
cationic protein (ECP) were determined in blood and
sputum,  and  myeloperoxidase  (MPO)  in  sputum.
Cytokines were determined in sputum supernatants
and in blood mononuclear cells after in vitro cultiva-
tion  with  and  without  stimulation.  The  wash-out
period between the two inhalation challenges was 2
weeks. The  sputum  inductions  for  baseline  values
were  performed  1  week  before  the  start  of  the
inhalation  challenges  (one  baseline  induction/sub-
ject)  and  blood  samples  were  taken  immediately
before each exposure.
The Ethics Committee of the Faculty of Medicine in
Gothenburg approved the study.
Inhalation of grifolan
Grifolan, a (1® 3)-b -D-glucan extracted from G. fron-
dosa, was suspended in 0.5M NaOH to dissolve the
triple helix and render the substance water soluble. It
was then diluted 600 times with pyrogen-free saline
to  a  final  concentration  of  8.3 m g/ml.  The  final
solution contained 0.8 mM NaOH and was adjusted
with HCl to pH 7.0. The saline and grifolan in saline
were  aerosolised  using  a  Pari  Boy  nebuliser  with
automatic dosing, giving  3 m l  per puff. The  subject
exhaled,  placed  the  nebuliser  in  the  mouth  and
started to inhale. Each subject inhaled five puffs  of
grifolan solution to a final dose of 125ng.
Differential cell counts in blood
Blood  samples  were  collected  in  ethylenedicrine
tetracicetic acid  (EDTA)  tubes,  and  total  leukocyte
counts were performed using  a microscope. Differ-
ential cell counts were made on smears stained with
May–Gr¨ unwald–Giemsa. The results were expressed
as 109 cells/l of blood.
Induced sputum
Sputum  induction was performed according to Pin
et  al.23 with  some  modifications.4 Five  percent
saline  was  nebulised  and  inhaled  over  a  period  of
20min. Ten  minutes  after  the  start  of  nebulisation
and every 5min thereafter, subjects interrupted the
inhalation and were asked to rinse their mouth and
throat carefully  and to cough sputum  into a sterile
plastic  container.  The  total  amount  of  hypertonic
saline  administered  was  20ml.  For  safety  reasons,
spirometry  measurements  were  performed  before
and  immediately  after  sputum  inductions,  using
standard techniques. A Vitalograph  model  S  with  a
PFT printer was used and calibrated every morning
with  a  1l  syringe. The  subjects  performed  at  least
three technically acceptable trials according to ATS
(American Thoracic Society) criteria, and the largest
values  for  the  forced  expiratory  volume  in  1sec
(FEV1)  and  the  forced  vital  capacity  (FVC)  were
registered and compared with predicted values.24
The volume of the collected sputum  sample was
determined, and an equal volume of Sputasol (Oxoid;
Unipath LTD, Basingstoke, UK) was added to obtain a
final  concentration  of  3.25 mM  dithiothreitol. The
samples were incubated in a shaking water bath at
37°C for 5–10min to ensure complete homogenisa-
tion. The  samples  were  transferred  into  tubes  and
centrifuged  at 600 ´ g for 5min. The supernatants
were aspirated and frozen at –70°C for later ECP, MPO
and  cytokine  determinations. The  cell  pellets  were
washed  twice  in  a  washing  solution  (Hanks  salt
solution + 5% fetal calf serum + 2% EDTA, adjusted to
pH 7.2). The total cell count and the cell viability were
determined using a B¨ urker chamber and trypan blue
exclusion.  Differential  cell  counts  were  made  on
smears stained with May–Gr¨ unwald–Giemsa. A cell
sample was considered adequate if, on differential cell
J. Thorn et al.
174 Mediators of Inflammation · Vol 10 · 2001counting,  it  contained  less  than  50%  squamous
epithelial  cells. The  results  were  expressed  as  109
cells/l of sputum.
Inflammatory markers
ECP was assayed in serum and sputum samples by a
fluorescent  enzyme  immunoassay  technique  (CAP
ECP FEIA; Pharmacia Diagnostics AB, Uppsala, Swe-
den)  and  expressed  as  m g/l.  MPO  was  assayed  in
sputum  samples by  an enzyme-linked immunoassay
(MPO-EIA; R&D Systems, UK) and expressed as m g/l.
Prior to the analyses, cell-free sputum samples were
treated  with  equal  volumes  of  0.4%  cetyltrimethy-
lammonium bromide (CTAB) (Calbiochem, CA, USA),
diluted in 0.25% phosphate-buffered saline and incu-
bated at room temperature for 1h. After centrifuga-
tion at 1500 ´ g for 10min, the supernatants were
aspirated and used for ECP and MPO determinations.
CTAB  was  used  to  decharge  the  ECP  and  MPO  to
optimise the immunoassays.
Cytokine release from blood mononuclear cells
and in induced sputum supernatants
Whole blood was collected in vacutainer cell prepara-
tion tubes (CPT tubes; Becton and Dickinson, USA)
and centrifuged for 20min at 1500 ´ g to collect the
mononuclear  cell  (MNC)  fraction.  The  MNC  was
washed  twice  in  Hank’s  salt  buffer,  supplemented
with 10% of homologue serum. The cells, 1 ´ 106/ml,
were  suspended  in  AIM-V  medium  (Gibco  BRL,
Paisley,  Scotland)  supplemented  with  2-mercaptoe-
thanol,  4 ´ 10–5M,  and  incubated without  or with
phytohaemagglutinin (PHA) (Murex Diagnostics Lim-
ited) to obtain a final concentration 0.005 mitogenic
units/ml. After 48h of incubation at 37°C and 5% CO2,
the supernatants were collected and stored at –70°C
until cytokine analysis.
TNF-a and IL-10 from unstimulated blood MNC and
in induced sputum were analysed using an enzyme-
linked  immunosorbent  assay  (ELISA)  kit  with  a
sensitivity  of  0.1pg/ml  (Quantikine  high  sensitive;
R&D Systems). TNF-a in PHA-stimulated MNC and IL-8
in  induced  sputum  were  analysed  using  PeliKine-
compact™  human  cytokine  ELISA  (CLB,  The
Netherlands).
Treatment of data
The differences between effect variables before and
24 and 72h after the exposures were analysed using
non-parametric  tests  (Wilcoxon’s  tests)  and  paired
sample  tests.  The  differences  between  the
(1® 3)-b -D-glucan and saline challenges were analysed
using non-parametric tests (Mann–Whitney U-test and
chi-squared test). Differences were considered statis-
tically significant at p < 0.05.
Results
Inflammatory markers, cytokines and cells in
induced sputum
The  results  of  the  determinations  of  ECP,  MPO,
cytokines and  cells  in  induced  sputum  before  and
24h after the challenges are shown in Table 1.
The amounts  of  ECP,  MPO, TNF-a and  IL-8  were
larger after the inhalation of saline and even higher
after  the  (1® 3)-b -D-glucan  inhalation. The  changes
(before–24h  after  inhalation)  induced  by  the
(1® 3)-b -D-glucan  inhalation  as  compared  with  the
changes induced  by  the saline  inhalation were  not
statistically significant. The same was found  for  the
number  of  neutrophils. The amounts of  IL-10  were
slightly lower after both inhalations as compared with
before.
No significant differences were observed 72h after
the  challenges  with  (1® 3)-b -D-glucan  and saline as
compared with before (data not shown).
Effects of inhaled (1® 3)-b -D-glucan
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Table 1. Amounts of ECP, MPO, TNF-a , IL-8 and IL-10 as well
as the number of cells (´ 10







(1 ® 3)-b -
D-glucan
inhalation
Subjects (n) 21 21 21
ECP (m g/l) 63 (58) 100 (84)* 122 (175)*
Median 41 88 98
Range 14–268 10–254 22–800
MPO (m g/l) 2456 (2307) 3531 (4436) 4030 (4127)
Median 949 1244 1937
Range 208–3740 561–8088 366–13316
TNF-a (pg/ml) 6.5 (4.7) 9.6 (8.9)* 12.5 (14.0)**
Median 4.3 5.5 5.2
Range 1.8–17.2 2.1–29.1 2.0–52.2
IL-8 (ng/ml) 4.7 (3.2) 5.6 (5.2) 8.3 (9.5)
Median 3.1 3.8 4.4
Range 1.3–11.6 1.6–12.4 0.9–41.7
IL-10 (pg/ml) 3.5 (2.0) 2.5 (1.5) 2.6 (1.2)
Median 2.8 2.2 2.1
Range 1.3–9.0 0.4–5.6 1.2–5.4
Eosinophils 0 (0.01) 0 (0) 0 (0)
Median 0 0 0
Range 0–0.1 0–0 0–0
Lymphocytes 0.05 (0.05) 0.07 (0.06) 0.07 (0.06)
Median 0.05 0.08 0.08
Range 0.01–0.15 0–0.17 0.01–0.20
Macrophages 0.8 (0.5) 0.7 (0.4) 0.9 (0.6)
Median 0.6 0.8 0.9
Range 0.2–2.1 0.1–1.6 0.4–2.6
Neutrophils 0.40 (0.40) 0.46 (0.56) 0.59 (0.70)*
Median 0.26 0.27 0.40
Range 0.09–1.6 0.07–0.7 0.07–2.2
Mean  values,  standard  deviations  in  parentheses,  medians  and
ranges  before  and  24h  after  inhalation  of  saline  or  125ng
(1® 3)-b -D-glucan are shown.
*p < 0.05, **p < 0.01.Inflammatory markers, cytokines and cells in
blood
In  blood,  no  significant  differences  in  any  of  the
variables were observed 24h after the challenges as
compared with before (data not shown).
The results of the determinations of ECP, TNF-a and
cells in blood before and 72h after the challenges are
shown in Table 2.
The  amounts  of  TNF-a from  unstimulated  and
stimulated MNC were slightly higher after the inhala-
tion  of  saline  as  compared  with  before. After  the
(1® 3)-b -D-glucan  inhalation,  the  amounts  were
instead decreased and significantly different from the
increase induced by the inhalation of saline alone in
stimulated MNC (p < 0.05).
The  number  of  eosinophils  was  not  influenced
after the inhalation of saline. After the inhalation of
(1® 3)-b -D-glucan,  however,  a  significantly  lower
number  of  eosinophils  were  found  as  compared
with  before.  The  change  in  eosinophil  numbers
induced by the (1® 3)-b -D-glucan inhalation as com-
pared with the change induced by the saline inhala-
tion was on the borderline for statistical significance
(–0.07;  95%  confidence  interval  (CI),  –0.14–0;
p=0.06).
Spirometry
No  significant  differences  in  lung  function  values
were observed 24h after the challenges as compared
with before (data not shown). At 72h, FEV1 values
were  slightly  higher  after  the  inhalation  of
(1® 3)-b -D-glucan as compared with before (107%, SD
= 15 versus 105%, SD = 14; p < 0.05). No significant
differences were observed after the  challenge with
saline  (106%,  SD  =  14  versus  107%,  SD  =  14;  not
significant). The change in FEV1 values induced by the
(1® 3)-b -D-glucan  inhalation  as  compared  with  the
change  induced by  the saline inhalation was statis-
tically significant (2.8%; 95% CI, 0.6–4.9; p < 0.05).
At all occasions of sputum induction, the FEV1 and
FVC values were significantly lower immediately after
hypertonic  saline  inhalation  as  compared  with
before.
Discussion
Spirometry  measurements,  blood  and  induced  spu-
tum samples were collected at 24 and 72h after the
challenges. The first post-exposure time was chosen
on the basis of results of previous experiments with
J. Thorn et al.
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(1 ® 3)-b -D-glucan
Before After
Subjects (n) 21 21 21 21
ECP (m g/l) 5.7 (2.6) 6.1 (3.6) 6.3 (3.9) 5.8 (3.3)
Median 6.0 5.6 5.6 6.3
Range 2.0–11.0 2.0–13.5 2.0–12.9 2.0–12.3
TNF-a , unstimulated
MNC (pg/ml) 12.8 (10.1) 14.1 (10.8) 12.2 (9.7) 9.2 (8.1)
Median 7.7 8.6 7.0 6.1
Range 3.8–40.5 2.9–36.2 3.1–32.7 2.8–29.4
TNF-a , stimulated
MNC (pg/ml) 3047 (1743) 4071 (2589) 4150 (2471) 3694 (1893)
Median 2783 3302 3454 3401
Range 1013–7608 1774–9796 969–9465 1311–7351
Eosinophils (n) 0.12 (0.09) 0.13 (0.12) 0.15 (0.11) 0.09 (0.07)*
Median 0.11 0.11 0.15 0.08
Range 0–0.36 0–0.58 0.02–0.48 0–0.27
Lymphocytes (n) 2.5 (0.6) 2.6 (0.8) 2.8 (0.6) 2.6 (0.7)
Median 2.7 2.4 2.7 2.6
Range 1.4–3.5 1.4–4.3 1.5–4.2 1.2–3.8
Monocytes (n) 0.18 (0.13) 0.17 (0.08) 0.15 (0.09) 0.14 (0.08)
Median 0.17 0.17 0.15 0.15
Range 0.03–0.46 0.03–0.34 0.06–0.37 0–0.27
Neutrophils (n) 3.4 (1.3) 3.4 (1.4) 2.8 (0.9) 3.4 (1.8)
Median 3.5 2.8 2.7 3.0
Range 1.5–6.0 1.9–7.2 1.2–4.8 1.7–8.8
Mean values, standard deviations in parentheses, medians and ranges before and 72h after inhalation of saline or 125ng (1 ® 3)-b -D-glucan are
shown.
*p < 0.05.LPS that showed respiratory and general effects at that
time.4 The post-exposure time of 72h was chosen on
the basis of a few preliminary  results  where symp-
toms after exposure to glucan persisted after 3 days.20
The (1® 3)-b -D-glucan dose was selected as it corre-
sponded to the threshold for inducing symptoms such
as throat and nose irritation, sore throat and headache
in  a  pilot  experiment  involving  two  subjects. As  a
comparison with the 125ng dose used in this study,
(1® 3)-b -D-glucan levels up to 366ng/m3 have been
measured  in  occupational  environments and  up  to
106ng/m3 in  homes  where  symptoms  have  been
reported.25,26
The induced sputum technique requires inhalation
of  hypertonic  saline.  As  this  may  influence  the
response to (1® 3)-b -D-glucan, the sputum inductions
for baseline values were performed 1 week before the
start of the inhalation challenges. To minimise the risk
of  an  influence  of  the  hypertonic  saline  on  the
endpoints  used,  the  sputum  inductions  were  per-
formed  at  least  48h  apart.4,27 At  all  occasions  of
sputum  induction,  the  FEV1 and  FVC  values  were
significantly  lower  immediately  after  hypertonic
saline  inhalation  as  compared  with  before.  This
confirms that hypertonic saline can induce a broncho-
constriction, as has been reported in previous stud-
ies.4,28 At 72h, the FEV1 values were slightly higher
after the inhalation of (1® 3)-b -D-glucan as compared
with the saline inhalation. These results indicate that
(1® 3)-b -D-glucan does not induce a bronchoconstric-
tion at the dose level used.
The  results  suggest  a  significant  increase  in  the
amounts  of  ECP  and TNF-a and  a  tendency  to  an
increased level of MPO in induced sputum after the
saline inhalation, indicating that saline has an inflam-
matory effect. Increased levels of these inflammatory
markers  have  been  found  in  previous  studies  on
airway  inflammation  and  after  organic  dust/LPS
exposures.25,29As (1® 3)-b -D-glucan was suspended in
saline,  the  increase  in  these  variables  after
(1® 3)-b -D-glucan inhalation was probably partly due
to saline. Although the changes were higher after the
(1® 3)-b -D-glucan  inhalation,  the  differences  to  the
saline  inhalation  alone  were  not  statistically  sig-
nificant.  Whether  (1® 3)-b -D-glucan  as  such  can
induce an additional inflammatory response has to be
investigated in future studies.
In  blood,  the  secretion  of  TNF-a was  slightly
increased after the saline inhalation both in unstimu-
lated  and  stimulated  mononuclear  cells  72h  after
exposure.  After  exposure  to  (1® 3)-b -D-glucan,  the
secretion was lower as compared with before. This
indicates that inhaled (1® 3)-b -D-glucan can induce a
depression of the TNF-a -producing capacity of blood
mononuclear  cells.  This  agrees  with  results  from
previous  studies.  In  a  guinea-pig  model,  the  neu-
trophil response in the airways to inhaled endotoxin
was abrogated in a dose-dependent way by a previous
exposure to (1® 3)-b -D-glucan.15 In mice, there was a
depression of inflammatory cytokines such as TNF-a
after pretreatment with (1® 3)-b -D-glucan.30
The  number  of  eosinophils  in  blood  was  sig-
nificantly decreased 72h after the (1® 3)-b -D-glucan
challenge as compared with before. This effect was
not observed after the saline inhalation. The eosino-
phil number in induced sputum was not increased,
suggesting that there was a recruitment of eosinophils
from  the  blood  to  the  lung  tissue.  This  is  in
accordance with findings observed after exposure to
(1® 3)-b -D-glucan  in  an  animal  model  where  an
increased number  of  eosinophils  was  found  in  the
airway epithelium.31
As (1® 3)-b -D-glucan,  we used grifolan. There are
several other forms of glucans, with different bonds
and branches, that have been investigated in animal
models. At  this  point,  no  comparisons  have  been
made of the relevance of different (1® 3)-b -D-glucans
or different (1® 3)-b -D-glucan preparations in human
subjects.  Thus,  no  conclusions  of  the  effects  on
humans of glucans in general can be drawn from the
results in this study.
In  conclusion,  the  results  suggest  that
(1® 3)-b -D-glucan in the dose used does not cause an
acute  neutrophil-dominated inflammatory response,
in contrast to inflammatory agents such as bacterial
endotoxin. The  decreased eosinophil  numbers  and
decrease in TNF-a production from stimulated mono-
nuclear  cells  in  blood  after  the  (1® 3)-b -D-glucan
challenge indicate a different type of response.
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